News

Melior Discovery, Inc. has recently announced that the United States Patent and Trademark Office (USTPO) granted the company a patent for MLR-1019, its Parkinson’s disease candidate. The patent includes the utilization of this therapeutic to address treatment for dyskinesia linked with L-DOPA therapy in Parkinson’s disease. “This recent patent award will…

Senior Helpers, one of the largest home senior care companies in the United States, recently announced it has been named the exclusive sponsor of online resources for caregiving for the Michael J. Fox Foundation for Parkinson’s Research. The Michael J. Fox Foundation is a nonprofit organization and a leading funder of Parkinson’s disease research throughout the world, committed…

Amarantus BioScience Holdings, Inc, a company that develops diagnostics and treatments for syndromes in the fields of neurology, psychiatry, ophthalmology and regenerative medicine, recently announced the opening of the first clinical site in its Phase 2b trial that will assess the efficacy of eltoprazine in treating patients with Parkinson’s…

Cynapsus Therapeutics Inc. (CTH) has been granted an additional patent for its sublingual apomorphine portfolio by the U.S. Patent and Trademark Office (USPTO). Cynapsus focuses on developing a therapeutic option to address the off-episodes in patients with Parkinson’s disease called APL-130277, and the new patent is owned solely by the company. Cynpasus received…

In a recent study published in the journal Neuron, a team of researchers at the University of Bonn and at the German Center for Neurodegenerative Diseases (DZNE) led by Prof. Stefan Remy were able to identify in mice brains specific neural cells linked to movement and navigation…

The National Parkinson Foundation (NPF) recently announced that an ongoing national research project comparing telemedicine-based healthcare provided by a Parkinson’s disease center to community-based care has achieved its target of enrolling 200 participants. The 200 enrollees suffering from Parkinson’s disease will be randomly assigned to receive either their usual care or to continue treatment plus meet a Parkinson’s expert…

According to the Mayo Clinic, current treatments are often unable to address the medical needs of Parkinson’s patients, since clinicians only have access to drugs or devices that manage symptoms. Nevertheless, several developments in immunology, cell biology and other fields have advanced the potential for regenerative medicine to make an impact on treating Parkinson’s disease patients in…

The CEO of NeuroDerm Ltd. has been invited to discuss the company’s achievements at the Jefferies 2015 Healthcare Conference, taking place next month in New York. Oded S. Lieberman, PhD, will present a corporate overview of the company, as well as novel treatments being developed by NeuroDerm for the treatment of moderate to severe Parkinson’s disease. The…

Researchers from the University of Florida have uncovered a biomarker that reveals the progression of Parkinson’s disease in the brain. This finding opens a new path toward improved diagnosis and treatment of the degenerative disease. The interdisciplinary research team compared brain images of Parkinson’s patients with images belonging to a control group for…

Biotie Therapies has announced an agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the company’s Phase 3 Parkinson’s disease study of tozadenant. The study (TOZ-PD) will evaluate both the safety and the efficacy of tozadenant in comparison to placebo in Parkinson’s patients currently…